{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:37:18Z","timestamp":1740123438128,"version":"3.37.3"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"MOE Key Laboratory of Tumor Molecular Biology","award":["50411651-2020-4"],"award-info":[{"award-number":["50411651-2020-4"]}]},{"name":"the Guangdong Basic and Applied Basic Research Foundation","award":["2021A1515011184"],"award-info":[{"award-number":["2021A1515011184"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803580","81402839"],"award-info":[{"award-number":["81803580","81402839"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LGF20B020001"],"award-info":[{"award-number":["LGF20B020001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10822-023-00510-8","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T07:01:35Z","timestamp":1685775695000},"page":"325-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Bo","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juntao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"key":"510_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","volume":"40","author":"L Chen","year":"2021","unstructured":"Chen L, Yin ZYL et al (2021) Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. J Exp Clin Cancer Res 40:345. https:\/\/doi.org\/10.1186\/s13046-021-02156-6","journal-title":"J Exp Clin Cancer Res"},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook MA, Reeser JW, Ernst G et al (2021) Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer 124:880\u2013892. https:\/\/doi.org\/10.1038\/s41416-020-01157-0","journal-title":"Br J Cancer"},{"key":"510_CR3","doi-asserted-by":"publisher","first-page":"1759720X2210848","DOI":"10.1177\/1759720X221084848","volume":"14","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan R, De Bergua JM, Arundel P et al (2022) Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies. Ther Adv Musculoskelet Dis 14:1759720X221084848. https:\/\/doi.org\/10.1177\/1759720X221084848","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"510_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC (2017) Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 17:318\u2013332. https:\/\/doi.org\/10.1038\/nrc.2017.8","journal-title":"Nat Rev Cancer"},{"key":"510_CR5","doi-asserted-by":"publisher","unstructured":"Markham A (2019) Erdafitinib: First Global approval. Drugs 79:1017\u20131021. https:\/\/doi.org\/10.1007\/s40265-019-01142-9","DOI":"10.1007\/s40265-019-01142-9"},{"key":"510_CR6","first-page":"923","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM (2020) Pemigatinib: First Approval Drugs 80:923\u2013929","journal-title":"Pemigatinib: First Approval Drugs"},{"key":"510_CR7","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.2147\/OTT.S272208","volume":"14","author":"J Yu","year":"2021","unstructured":"Yu J, Mahipal A, Kim R (2021) Targeted therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the clinical potential of Infigratinib. OncoTargets Ther 14:5145\u20135160. https:\/\/doi.org\/10.2147\/OTT.S272208","journal-title":"OncoTargets Ther"},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M et al (2022) FIGHT-101, a first-in-human study of potent and selective FGFR 1\u20133 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol 33:522\u2013533. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.001","journal-title":"Ann Oncol"},{"key":"510_CR9","doi-asserted-by":"publisher","first-page":"103091","DOI":"10.1016\/j.critrevonc.2020.103091","volume":"155","author":"A Mahipal","year":"2020","unstructured":"Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R (2020) Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol 155:103091. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103091","journal-title":"Crit Rev Oncol Hematol"},{"key":"510_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/liv.12462","volume":"34","author":"HR Mellor","year":"2014","unstructured":"Mellor HR (2014) Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Liver Int 34:e1\u20139. https:\/\/doi.org\/10.1111\/liv.12462","journal-title":"Liver Int"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","volume":"297","author":"J Gattineni","year":"2009","unstructured":"Gattineni J, Bates C, Twombley K et al (2009) FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297:F282\u2013291. https:\/\/doi.org\/10.1152\/ajprenal.90742.2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"510_CR12","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.aaw3472","volume":"363","author":"KM Haigis","year":"2019","unstructured":"Haigis KM, Cichowski K, Elledge SJ (2019) Tissue-specificity in cancer: the rule, not the exception. Science 363:1150\u20131151. https:\/\/doi.org\/10.1126\/science.aaw3472","journal-title":"Science"},{"key":"510_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"ICGC\/TCGA","year":"2020","unstructured":"ICGC\/TCGA (2020) Pan-cancer analysis of whole genomes. Nature 578:82\u201393. https:\/\/doi.org\/10.1038\/s41586-020-1969-6","journal-title":"Nature"},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306\u201313311. https:\/\/doi.org\/10.1073\/pnas.0405220101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"510_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/science.1101637","volume":"305","author":"R Sordella","year":"2004","unstructured":"Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163\u20131167. https:\/\/doi.org\/10.1126\/science.1101637","journal-title":"Science"},{"key":"510_CR16","doi-asserted-by":"publisher","first-page":"831146","DOI":"10.3389\/fgene.2022.831146","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Dong X, Yang F, Xing N (2022) Comparative analysis of differentially mutated genes in non-muscle and muscle-invasive bladder Cancer in the Chinese Population by whole exome sequencing. Front Genet 13:831146. https:\/\/doi.org\/10.3389\/fgene.2022.831146","journal-title":"Front Genet"},{"key":"510_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/ajhp\/zxz329","volume":"77","author":"K Roubal","year":"2020","unstructured":"Roubal K, Myint ZW, Kolesar JM (2020) Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer. Am J Health Syst Pharm 77:346\u2013351. https:\/\/doi.org\/10.1093\/ajhp\/zxz329","journal-title":"Am J Health Syst Pharm"},{"key":"510_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/annonc\/mdw636","volume":"28","author":"P Chandrani","year":"2017","unstructured":"Chandrani P, Prabhash K, Prasad R et al (2017) Drug-sensitive FGFR3 mutations in lung adenocarcinoma. Ann Oncol 28:597\u2013603. https:\/\/doi.org\/10.1093\/annonc\/mdw636","journal-title":"Ann Oncol"},{"key":"510_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11604-021-01230-5","volume":"40","author":"N Ota","year":"2022","unstructured":"Ota N, Yoshimoto Y, Darwis NDM et al (2022) High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy. Jpn J Radiol 40:534\u2013541. https:\/\/doi.org\/10.1007\/s11604-021-01230-5","journal-title":"Jpn J Radiol"},{"key":"510_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-4598-4-15","volume":"4","author":"C Rosty","year":"2005","unstructured":"Rosty C, Aubriot MH, Cappellen D et al (2005) Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer 4:15. https:\/\/doi.org\/10.1186\/1476-4598-4-15","journal-title":"Mol Cancer"},{"key":"510_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 20:551\u2013569. https:\/\/doi.org\/10.1038\/s41573-021-00195-4","journal-title":"Nat Rev Drug Discov"},{"key":"510_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","volume":"138","author":"SA Rosenzweig","year":"2018","unstructured":"Rosenzweig SA (2018) Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res 138:71\u201398. https:\/\/doi.org\/10.1016\/bs.acr.2018.02.003","journal-title":"Adv Cancer Res"},{"key":"510_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal L, Saha SK, Liu LY et al (2017) Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov 7:252\u2013263. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1000","journal-title":"Cancer Discov"},{"key":"510_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/onc.2012.319","volume":"32","author":"V Chell","year":"2013","unstructured":"Chell V, Balmanno K, Little AS et al (2013) Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 32:3059\u20133070. https:\/\/doi.org\/10.1038\/onc.2012.319","journal-title":"Oncogene"},{"key":"510_CR25","doi-asserted-by":"publisher","first-page":"24252","DOI":"10.18632\/oncotarget.8132","volume":"7","author":"H Patani","year":"2016","unstructured":"Patani H, Bunney TD, Thiyagarajan N et al (2016) Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget 7:24252\u201324268. https:\/\/doi.org\/10.18632\/oncotarget.8132","journal-title":"Oncotarget"},{"key":"510_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41589-019-0455-7","volume":"16","author":"L Chen","year":"2020","unstructured":"Chen L, Marsiglia WM, Chen H, Katigbak J, Mohammadi M (2020) Molecular basis for receptor tyrosine kinase a-loop tyrosine transphosphorylation. Nat Chem Biol 16:1\u201311. https:\/\/doi.org\/10.1038\/s41589-019-0455-7","journal-title":"Nat Chem Biol"},{"key":"510_CR27","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"M A.Waterhouse","year":"2018","unstructured":"A.Waterhouse M, Bertoni S, Bienert et al (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296\u2013W303. https:\/\/doi.org\/10.1093\/nar\/gky427","journal-title":"Nucleic Acids Res"},{"key":"510_CR28","unstructured":"Schrodinger LLC (2015) The PyMOL Molecular Graphics System, Version 2.5."},{"key":"510_CR29","doi-asserted-by":"publisher","unstructured":"Abraham MJ, Murtola T, Schulz R et al (2015) Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers - sciencedirect. SoftwareX, s1-2 19\u201325, https:\/\/doi.org\/10.1016\/j.softx.2015.06.001","DOI":"10.1016\/j.softx.2015.06.001"},{"key":"510_CR30","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/jcc.23354","volume":"34","author":"J Huang","year":"2013","unstructured":"Huang J, Mackerell AD (2013) Charmm36 all-atom additive protein force field: validation based on comparison to nmr data. J Comput Chem 34:2135\u20132145. https:\/\/doi.org\/10.1002\/jcc.23354","journal-title":"J Comput Chem"},{"key":"510_CR31","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","volume":"22","author":"JA Tucker","year":"2014","unstructured":"Tucker JA, Klein T, Breed J, Breeze AL, Norman RA (2014) Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Structure 22:1764\u20131774. https:\/\/doi.org\/10.1016\/j.str.2014.09.019","journal-title":"Structure"},{"key":"510_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ebiom.2015.02.009","volume":"2","author":"TD Bunney","year":"2015","unstructured":"Bunney TD, Wan S, Thiyagarajan N et al (2015) The effect of mutations on drug sensitivity and kinase activity of fibroblast growth factor receptors: a combined experimental and theoretical study. EBioMedicine 2:194\u2013204. https:\/\/doi.org\/10.1016\/j.ebiom.2015.02.009","journal-title":"EBioMedicine"},{"key":"510_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe K, Hatcher E, Acharya C, CHARMM General Force Field et al (2010) A Force field for Drug-Like Molecules Compatible with the CHARMM All-Atom Additive Biological Force Field. J Comput Chem 31:671\u2013690. https:\/\/doi.org\/10.1002\/jcc.21367","journal-title":"J Comput Chem"},{"key":"510_CR34","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/jcc.23067","volume":"33","author":"W Yu","year":"2012","unstructured":"Yu W, He X, Vanommeslaeghe K, MacKerell AD Jr (2012) Extension of the CHARMM General Force Field to Sulfonyl-Containing Compounds and its utility in Biomolecular Simulations. J Comput Chem 33:2451\u20132468. https:\/\/doi.org\/10.1002\/jcc.23067","journal-title":"J Comput Chem"},{"key":"510_CR35","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/ci300363c","volume":"52","author":"K Vanommeslaeghe","year":"2012","unstructured":"Vanommeslaeghe K, MacKerell AD Jr (2012) Automation of the CHARMM General Force Field (CGenFF) I: bond perception and atom typing. J Chem Inf Model 52:3144\u20133154. https:\/\/doi.org\/10.1021\/ci300363c","journal-title":"J Chem Inf Model"},{"key":"510_CR36","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1021\/ci3003649","volume":"52","author":"K Vanommeslaeghe","year":"2012","unstructured":"Vanommeslaeghe K, Raman EP, MacKerell AD Jr (2012) Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges. J Chem Inf Model 52:3155\u20133168. https:\/\/doi.org\/10.1021\/ci3003649","journal-title":"J Chem Inf Model"},{"key":"510_CR37","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller 3rd","year":"2012","unstructured":"Miller BR 3rd, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE (2012) MMPBSA.py: an efficient program for end-state Free Energy Calculations. J Chem Theory Comput 8:3314\u20133321. https:\/\/doi.org\/10.1021\/ct300418h","journal-title":"J Chem Theory Comput"},{"key":"510_CR38","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.6408973","author":"J Li","year":"2022","unstructured":"Li J (2022) gmxtools Zenodo. https:\/\/doi.org\/10.5281\/zenodo.6408973","journal-title":"gmxtools Zenodo"},{"key":"510_CR39","doi-asserted-by":"publisher","unstructured":"Lang EJM, Heyes LC, Jameson GB, Parker EJ Calculated pKa variations expose dynamic allosteric communication networks. J Am Chem Soc 138 (2016) 2036\u20132045, https:\/\/doi.org\/10.1021\/jacs.5b13134","DOI":"10.1021\/jacs.5b13134"},{"key":"510_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.compbiolchem.2015.07.013","volume":"58","author":"XY Guo","year":"2015","unstructured":"Guo XY, Qi RP, Xu DG, Liu XH, Yang X (2015) Structural and energetic insight into the interactions between the benzolactam inhibitors and tumor marker HSP90\u03b1. Comput Biol Chem 58:182\u2013191. https:\/\/doi.org\/10.1016\/j.compbiolchem.2015.07.013","journal-title":"Comput Biol Chem"},{"key":"510_CR41","first-page":"932","volume":"1","author":"J K\u00e4stner","year":"2011","unstructured":"K\u00e4stner J (2011) Umbrella sampling. Wiley Interdisciplinary Reviews: Computational Molecular Science 1:932\u2013942","journal-title":"Wiley Interdisciplinary Reviews: Computational Molecular Science"},{"key":"510_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s0010-4655(00)00215-0","volume":"135","author":"M Souaille","year":"2001","unstructured":"Souaille M, Roux Bt (2001) Extension to the weighted histogram analysis method: combining umbrella sampling with free energy calculations. Comput Phys Commun 135:40\u201357. https:\/\/doi.org\/10.1016\/s0010-4655(00)00215-0","journal-title":"Comput Phys Commun"},{"key":"510_CR43","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/jcc.540130812","volume":"13","author":"S Kumar","year":"1992","unstructured":"Kumar S, Rosenberg JM, Bouzida D, Swendsen RH, Kollman PA (1992) The weighted histogram analysis method for free-energy calculations on biomolecules. I. The method. J Comput Chem 13:1011\u20131021. https:\/\/doi.org\/10.1002\/jcc.540130812","journal-title":"J Comput Chem"},{"key":"510_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1021\/ct0502864","volume":"3","author":"JD Chodera","year":"2007","unstructured":"Chodera JD, Swope WC, Pitera JW, Seok C, Dill KA (2007) Use of the weighted histogram analysis method for the analysis of simulated and parallel tempering simulations. J Chem Theory Comput 3:26\u201341. https:\/\/doi.org\/10.1021\/ct0502864","journal-title":"J Chem Theory Comput"},{"key":"510_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrm3528","volume":"14","author":"R Goetz","year":"2013","unstructured":"Goetz R, Mohammadi M (2013) Exploring mechanisms of FGF signaling through the lens of structural biology. Nat Rev Mol Cell Biol 14:166\u2013180. https:\/\/doi.org\/10.1038\/nrm3528","journal-title":"Nat Rev Mol Cell Biol"},{"key":"510_CR46","doi-asserted-by":"publisher","first-page":"21137","DOI":"10.7554\/eLife.21137","volume":"6","author":"H Chen","year":"2017","unstructured":"Chen H, Marsiglia WM, Cho MK et al (2017) Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. eLife 6:21137. https:\/\/doi.org\/10.7554\/eLife.21137","journal-title":"eLife"},{"key":"510_CR47","doi-asserted-by":"publisher","first-page":"17928","DOI":"10.1039\/c7cp02110k","volume":"19","author":"C Lefebvre","year":"2017","unstructured":"Lefebvre C, Rubez G, Khartabil H, Boisson JC, Contreras-Garc\u00eda J, H\u00e9non E (2017) Accurately extracting the signature of intermolecular interactions present in the NCI plot of the reduced density gradient versus electron density. Phys Chem Chem Phys 19:17928\u201317936. https:\/\/doi.org\/10.1039\/c7cp02110k","journal-title":"Phys Chem Chem Phys"},{"key":"510_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/jcc.26812","volume":"43","author":"T Lu","year":"2022","unstructured":"Lu T, Chen Q (2022) Independent gradient model based on Hirshfeld partition: a new method for visual study of interactions in chemical systems. J Comput Chem 43:539\u2013555. https:\/\/doi.org\/10.1002\/jcc.26812","journal-title":"J Comput Chem"},{"key":"510_CR49","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/jcc.22885","volume":"33","author":"T Lu","year":"2012","unstructured":"Lu T, Chen F (2012) Multiwfn: a multifunctional wavefunction analyzer. J Comput Chem 33:580\u2013592. https:\/\/doi.org\/10.1002\/jcc.22885","journal-title":"J Comput Chem"},{"key":"510_CR50","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adri\u00e1n FJ, Jahnke W et al (2010) Targeting bcr-abl by combining allosteric with ATP-binding-site inhibitors. Nature 463:501\u2013506. https:\/\/doi.org\/10.1038\/nature08675","journal-title":"Nature"},{"key":"510_CR51","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W et al (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543:733\u2013737. https:\/\/doi.org\/10.1038\/nature21702","journal-title":"Nature"},{"key":"510_CR52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1109\/TCBB.2020.2995569","volume":"19","author":"R Qureshi","year":"2020","unstructured":"Qureshi R, Ghosh A, Yan H (2020) Correlated motions and dynamics in different domains of EGFR with L858R and T790M mutations. IEEE\/ACM Trans Comput Biol Bioinform 19:383\u2013394. https:\/\/doi.org\/10.1109\/TCBB.2020.2995569","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"key":"510_CR53","doi-asserted-by":"publisher","unstructured":"Girvan M, Newman ME (2002) Community structure in social and biological networks, Proc. Natl. Acad. Sci. U.S.A. 99 7821\u20137826, https:\/\/doi.org\/10.1073\/pnas.122653799","DOI":"10.1073\/pnas.122653799"},{"key":"510_CR54","doi-asserted-by":"publisher","first-page":"20452056","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine PR, Mooney L, Kilgour E et al (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72:20452056. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3034","journal-title":"Cancer Res"},{"key":"510_CR55","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","volume":"105","author":"S Trudel","year":"2005","unstructured":"Trudel S, Li ZH, Wei E et al (2005) CHIR\u2013258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105:2941\u20132948. https:\/\/doi.org\/10.1182\/blood-2004-10-3913","journal-title":"Blood"},{"key":"510_CR56","doi-asserted-by":"publisher","unstructured":"Angibaud PR et al (2014) Discovery of JNJ\u201342756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment-based approach. Cancer Res 74 Suppl(abstr 4748). https:\/\/doi.org\/10.1158\/1538-7445.AM2014-4748","DOI":"10.1158\/1538-7445.AM2014-4748"},{"key":"510_CR57","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","volume":"49","author":"MF Adasme","year":"2021","unstructured":"Adasme MF, Linnemann KL, Bolz SN et al (2021) PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res 49:W530\u2013W534. https:\/\/doi.org\/10.1093\/nar\/gkab294","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"510_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17460441.2018.1403419","volume":"13","author":"X Liu","year":"2012","unstructured":"Liu X, Shi D, Zhou S, Liu H, Liu H, Yao X (2012) Molecular dynamics simulations and novel drug discovery. Expert Opin Drug Discov 13(1):23\u201337. https:\/\/doi.org\/10.1080\/17460441.2018.1403419","journal-title":"Expert Opin Drug Discov"},{"issue":"39","key":"510_CR59","doi-asserted-by":"publisher","first-page":"12692","DOI":"10.1021\/jp104753t","volume":"114","author":"SR Campos","year":"2010","unstructured":"Campos SR, Machuqueiro M, Baptista AM (2010) Constant-pH molecular dynamics simulations reveal a \u03b2-rich form of the human prion protein. J Phys Chem B 114(39):12692\u201312700. https:\/\/doi.org\/10.1021\/jp104753t","journal-title":"J Phys Chem B"},{"issue":"5","key":"510_CR60","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bpj.2013.12.053","volume":"106","author":"W Chen","year":"2014","unstructured":"Chen W, van der Kamp MW, Daggett V (2014) Structural and dynamic properties of the human prion protein. Biophys J 106(5):1152\u20131163. https:\/\/doi.org\/10.1016\/j.bpj.2013.12.053","journal-title":"Biophys J"},{"key":"510_CR61","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00018-003-3455-3","volume":"61","author":"S Santini","year":"2004","unstructured":"Santini S, Derreumaux P (2004) Helix H1 of the prion protein is rather stable against environmental perturbations: molecular dynamics of mutation and deletion variants of PrP (90\u2013231). Cell Mol Life Sci 61:951\u2013960. https:\/\/doi.org\/10.1007\/s00018-003-3455-3","journal-title":"Cell Mol Life Sci"},{"key":"510_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1021\/mp900131p","volume":"7","author":"H Liu","year":"2010","unstructured":"Liu H, Yao X (2010) Molecular basis of the interaction for an essential subunit PA \u2013 PB1 in influenza virus RNA polymerase: insights from molecular dynamics simulation and free energy calculation. Mol Pharm 7:75\u201385. https:\/\/doi.org\/10.1021\/mp900131p","journal-title":"Mol Pharm"},{"key":"510_CR63","doi-asserted-by":"publisher","first-page":"A43","DOI":"10.1021\/mp900131p","volume":"90","author":"A Sharon","year":"2011","unstructured":"Sharon A, Balaraju T, Bal C (2011) A catalytic 3D model development of HIV-integrase and drug resistance understanding by molecular dynamics simulation. Antiviral Res 90:A43\u2013A44. https:\/\/doi.org\/10.1021\/mp900131p","journal-title":"Antiviral Res"},{"issue":"4","key":"510_CR64","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/molecules23040767","volume":"23","author":"YL Pan","year":"2018","unstructured":"Pan YL, Liu YL, Chen JZ (2018) Computational Simulation Studies on the binding selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in complexes with FGFR1 and FGFR4. Molecules 23(4):767. https:\/\/doi.org\/10.3390\/molecules23040767","journal-title":"Molecules"},{"issue":"5","key":"510_CR65","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1039\/c6cp07964d","volume":"19","author":"W Fu","year":"2017","unstructured":"Fu W, Chen L, Wang Z et al (2017) Theoretical studies on FGFR isoform selectivity of FGFR1\/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations. Phys Chem Chem Phys 19(5):3649\u20133659. https:\/\/doi.org\/10.1039\/c6cp07964d","journal-title":"Phys Chem Chem Phys"},{"issue":"1","key":"510_CR66","doi-asserted-by":"publisher","first-page":"16593","DOI":"10.1038\/s41598-021-96159-0","volume":"11","author":"F Dehghanian","year":"2010","unstructured":"Dehghanian F, Alavi S (2010) Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance. Sci Rep 11(1):16593. https:\/\/doi.org\/10.1038\/s41598-021-96159-0","journal-title":"Sci Rep"},{"key":"510_CR67","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ijbiomac.2019.05.138","volume":"135","author":"C Wu","year":"2019","unstructured":"Wu C, Chen X, Chen D et al (2019) Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies. Int J Biol Macromol 135:294\u2013302. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.05.138","journal-title":"Int J Biol Macromol"},{"key":"510_CR68","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/j.ddtec.2012.07.007","volume":"10","author":"JP Changeux","year":"2013","unstructured":"Changeux JP (2013) The concept of allosteric modulation: an overview. Drug Discov Today Technol 10:e223\u2013e228. https:\/\/doi.org\/10.1016\/j.ddtec.2012.07.007","journal-title":"Drug Discov Today Technol"},{"issue":"8","key":"510_CR69","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.drudis.2022.03.012","volume":"27","author":"D Ni","year":"2022","unstructured":"Ni D, Liu Y, Kong R, Yu Z, Lu S, Zhang J (2022) Computational elucidation of allosteric communication in proteins for allosteric drug design. Drug Discov Today 27(8):2226\u20132234. https:\/\/doi.org\/10.1016\/j.drudis.2022.03.012","journal-title":"Drug Discov Today"},{"key":"510_CR70","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41589-018-0150-0","volume":"14","author":"Z Huang","year":"2018","unstructured":"Huang Z, Zhao J, Deng W et al (2018) Identification of a cellularly active SIRT6 allosteric activator. Nat Chem Biol 14:1118\u20131126. https:\/\/doi.org\/10.1038\/s41589-018-0150-0","journal-title":"Nat Chem Biol"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-023-00510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-023-00510-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-023-00510-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T10:04:57Z","timestamp":1686996297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-023-00510-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1007\/s10822-023-00510-8","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}